Search Results

You are looking at 1 - 4 of 4 items for

  • Author: D W Ray x
  • Refine by access: All content x
Clear All Modify Search
D W Ray
Search for other papers by D W Ray in
Google Scholar
PubMed
Close

Both generalised and tissue-specific glucocorticoid resistance is increasingly being recognised. In one study, 1–2% of patients evaluated for adrenal disorders were glucocorticoid-resistant (Werner et al. 1992). At the molecular level, resistance to glucocorticoids is usually defined using specific markers. Some cells, such as lymphocytes, exhibit a very clear phenotypic change in response to glucocorticoids, enabling this to be used as a marker of glucocorticoid action (Kaspers et al. 1994). In most cells, however, changes in target gene expression are used. Either endogenous or transfected genes can be used; however, endogenous genes are often subject to tissuespecific regulation, and measurement of the steady-state mRNA level is an insensitive measure of glucocorticoid action. Transfection of short, carefully defined sequences of glucocorticoid-regulated DNA linked to a suitable reporter gene (Fig. 1) enables small differences in the EC50 and Vmax values of glucocorticoid action to be confidently measured (Ray et al. 1994b). Typically, positively

Restricted access
C E Waters
Search for other papers by C E Waters in
Google Scholar
PubMed
Close
,
A Stevens
Search for other papers by A Stevens in
Google Scholar
PubMed
Close
,
A White
Search for other papers by A White in
Google Scholar
PubMed
Close
, and
D W Ray
Search for other papers by D W Ray in
Google Scholar
PubMed
Close

Human small cell lung carcinoma (SCLC) tumours exhibit neuroendocrine differentiation, secreting hormones such as ACTH and related peptides. While glucocorticoids inhibit ACTH secretion from the pituitary, this does not occur in SCLC tumours and SCLC cell lines. Failure of glucocorticoids to suppress ACTH peptides is accompanied by a global lack of glucocorticoid action in a number of SCLC cell lines.

In the human SCLC cell line, COR L103, activation of a human tyrosine aminotransferase (TAT3)-luciferase reporter gene is resistant to glucocorticoids despite similar glucocorticoid receptor (GR) expression to the glucocorticoid-sensitive A549 human lung cancer cell line; moreover, the GR is free of deleterious mutations. Over-expression of a wild-type GR restores glucocorticoid regulation of TAT3-luciferase, and this is enhanced when the activation function (AF)-2 domain is deleted but much reduced when the AF-1 domain is deleted. This suggests aberrant AF-2 activation domain function. We identified defective steroid receptor co-activator 1 (SRC1) recruitment to the GR AF-2 in COR L103 cells, although SRC1 was successfully recruited to the steroid X receptor with rifampicin, suggesting a defect in the GR. Analysis of other GR C-terminal co-factors identified increased expression of nuclear co-repressor (NCoR) in COR L103 cells. To determine the impact of this, NCoR was over-expressed in A549 cells, where it reduced GR transactivation by 55%.

In summary, glucocorticoid resistance is associated with altered SRC protein recruitment and increased expression of NCoR in these SCLC cells, suggesting that glucocorticoid sensitivity may be modified by subtle changes in co-factor recruitment.

Free access
A McMaster Medicine, Faculty of Life Sciences, Centre for Molecular
Medicine, Faculty of Life Sciences, Centre for Molecular

Search for other papers by A McMaster in
Google Scholar
PubMed
Close
,
T Chambers Medicine, Faculty of Life Sciences, Centre for Molecular

Search for other papers by T Chambers in
Google Scholar
PubMed
Close
,
Q-J Meng Medicine, Faculty of Life Sciences, Centre for Molecular

Search for other papers by Q-J Meng in
Google Scholar
PubMed
Close
,
S Grundy Medicine, Faculty of Life Sciences, Centre for Molecular

Search for other papers by S Grundy in
Google Scholar
PubMed
Close
,
A S I Loudon Medicine, Faculty of Life Sciences, Centre for Molecular

Search for other papers by A S I Loudon in
Google Scholar
PubMed
Close
,
R Donn Medicine, Faculty of Life Sciences, Centre for Molecular
Medicine, Faculty of Life Sciences, Centre for Molecular

Search for other papers by R Donn in
Google Scholar
PubMed
Close
, and
D W Ray Medicine, Faculty of Life Sciences, Centre for Molecular

Search for other papers by D W Ray in
Google Scholar
PubMed
Close

There is increasing evidence that temporal factors are important in allowing cells to gain additional information from external factors, such as hormones and cytokines. We sought to discover how cell responses to glucocorticoids develop over time, and how the response kinetics vary according to ligand structure and concentration, and hence have developed a continuous gene transcription measurement system, based on an interleukin-6 (IL-6) luciferase reporter gene. We measured the time to maximal response, maximal response and integrated response, and have compared these results with a conventional, end point glucocorticoid bioassay. We studied natural glucocorticoids (corticosterone and cortisol), synthetic glucocorticoids (dexamethasone) and glucocorticoid precursors with weak, or absent bioactivity. We found a close correlation between half maximal effective concentration (EC50) for maximal response, and for integrated response, but with consistently higher EC50 for the latter. There was no relation between the concentration of ligand and the time to maximal response. A comparison between conventional end point assays and real-time measurement showed similar effects for dexamethasone and hydrocortisone, with a less effective inhibition of IL-6 seen with corticosterone. We profiled the activity of precursor steroids, and found pregnenolone, progesterone, 21-hydroxyprogesterone and 17-hydroxyprogesterone all to be ineffective in the real-time assay, but in contrast, progesterone and 21-hydroxyprogesterone showed an IL-6 inhibitory activity in the end point assay. Taken together, our data show how ligand concentration can alter the amplitude of glucocorticoid response, and also that a comparison between real-time and end point assays reveals an unexpected diversity of the function of glucocorticoid precursor steroids, with implications for human disorders associated with their overproduction.

Open access
Elizabeth K Fletcher Centre for Endocrinology and Metabolism, Hudson Institute of Medical Research, Clayton, Victoria, Australia
Department of Physiology, The University of Melbourne, Parkville, Victoria, Australia
Tufts Medical Center, Boston, Massachusetts, USA

Search for other papers by Elizabeth K Fletcher in
Google Scholar
PubMed
Close
,
Monica Kanki Centre for Endocrinology and Metabolism, Hudson Institute of Medical Research, Clayton, Victoria, Australia

Search for other papers by Monica Kanki in
Google Scholar
PubMed
Close
,
James Morgan Centre for Endocrinology and Metabolism, Hudson Institute of Medical Research, Clayton, Victoria, Australia

Search for other papers by James Morgan in
Google Scholar
PubMed
Close
,
David W Ray NIHR Oxford Biomedical Research Centre, John Radcliffe Hospital, Oxford, UK
Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK

Search for other papers by David W Ray in
Google Scholar
PubMed
Close
,
Lea M Delbridge Department of Physiology, The University of Melbourne, Parkville, Victoria, Australia

Search for other papers by Lea M Delbridge in
Google Scholar
PubMed
Close
,
Peter J Fuller Centre for Endocrinology and Metabolism, Hudson Institute of Medical Research, Clayton, Victoria, Australia

Search for other papers by Peter J Fuller in
Google Scholar
PubMed
Close
,
Colin D Clyne Centre for Endocrinology and Metabolism, Hudson Institute of Medical Research, Clayton, Victoria, Australia

Search for other papers by Colin D Clyne in
Google Scholar
PubMed
Close
, and
Morag J Young Centre for Endocrinology and Metabolism, Hudson Institute of Medical Research, Clayton, Victoria, Australia

Search for other papers by Morag J Young in
Google Scholar
PubMed
Close

We previously identified a critical pathogenic role for mineralocorticoid receptor (MR) activation in cardiomyocytes that included a potential interaction between the MR and the molecular circadian clock. While glucocorticoid regulation of the circadian clock is undisputed, studies on MR interactions with circadian clock signalling are limited. We hypothesised that the MR influences cardiac circadian clock signalling, and vice versa. Aldosterone or corticosterone (10 nM) regulated Cry1, Per1, Per2 and ReverbA (Nr1d1) gene expression patterns in H9c2 cells over 24 h. MR-dependent regulation of circadian gene promoters containing GREs and E-box sequences was established for CLOCK, Bmal, CRY1 and CRY2, PER1 and PER2 and transcriptional activators CLOCK and Bmal modulated MR-dependent transcription of a subset of these promoters. We also demonstrated differential regulation of MR target gene expression in hearts of mice 4 h after administration of aldosterone at 08:00 h vs 20:00 h. Our data support MR regulation of a subset of circadian genes, with endogenous circadian transcription factors CLOCK and BMAL modulating the response. This unsuspected relationship links MR in the heart to circadian rhythmicity at the molecular level and has important implications for the biology of MR signalling in response to aldosterone as well as cortisol. These data are consistent with MR signalling in the brain where, like the heart, it preferentially responds to cortisol. Given the undisputed requirement for diurnal cortisol release in the entrainment of peripheral clocks, the present study highlights the MR as an important mechanism for transducing the circadian actions of cortisol in addition to glucocorticoid receptor (GR) in the heart.

Free access